With 57% Market Share Across Key Steroid APIs, Why Is It Betting Big on Insulin and Alternative Proteins?

Symbiotec Pharmalab enters the listed space with a strong position in steroid and hormone APIs, backed by three decades of manufacturing and regulatory experience. The company reported a 57% average market share across its top five products in FY26, including progesterones, hydrocortisones, testosterone, betamethasone and methylprednisolone.

But the bigger story is the company’s attempt to use its fermentation and biotechnology capabilities to build new businesses in insulin drug substance and alternative-protein biomanufacturing. 

With customer-backed contracts already in place, Symbiotec is moving from being predominantly a steroid API manufacturer toward becoming a broader biotechnology and CDMO platform. With a market cap of Rs 6,450 crore, the shares of Symbiotec Pharmalab Ltd are trading at Rs 1,000 and are trading at a PE of 65 compared to their industry’s PE of 35.

What Are Biotech and CDMO?

Biotechnology, commonly referred to as ‘biotech’, involves the application of biological systems and processes for product development or manufacture. In pharmaceutical and industrial manufacturing processes, one important application of biotechnology involves fermentation, which utilises biological systems for producing certain targeted molecules and ingredients on a large-scale basis. According to information published by Symbiotec, the company has had an established base in fermentation biotechnology since 2008.

CDMO stands for ‘Contract Development and Manufacturing Organisation’. The purpose of a CDMO is to assist a client company with developing, scaling up, and manufacturing products instead of the client needing to establish all necessary manufacturing capacity internally. 

Symbiotec plans to leverage its fermentation capacity to extend into CDMO and biomanufacturing services that include both scale-up and downstream processing. Explicitly stated in management guidance is the development of CDMO and CMO services in biopharma/biomanufacturing as growth opportunities.

Therefore, it should be noted that Symbiotec will be truly establishing a presence within the CDMO sector, but a better description would be a start-up CDMO operation that leverages biotechnology.

Why Is Symbiotec Expanding? 

The rationale behind this expansion comes from internal expertise built over time. Symbiotec has extensive experience in fermentation and biological technologies, and management feels these can be leveraged beyond its current steroid API product line.

Thus, there is intent to move upstream in the value chain. Rather than manufacture only its own APIs, it could potentially assist biotech/pharma firms in scaling their products from the development stage through to commercial production. Indeed, management specifically emphasized customer pain points related to the problem of scaling and downstream processing in commercialisation after developing breakthrough innovations in lab settings.

This is also evident in the size of its capital expenditure. As of June 2026, Symbiotec had incurred Rs 1,475 crore of cumulative gross capex, with total gross capex forecasted to grow to Rs 1,666 crore by FY27. Within this, CDMO services constituted Rs 471 crore, set to increase to Rs 584 crore by FY27. Symbiotec anticipates that about Rs 1,000 crore worth of its capex will start generating revenues within the next six to 12 months.

A Strong Steroid Core 

Although the new ventures have captured the imagination of investors, the steroid APIs business continues to form the core of Symbiotec. It produces approximately 60 steroid/hormone APIs, holds 44 US DMFs and 25 European CPs, and caters to more than 200 customers across more than 40 nations. According to the management, almost 70% of the company’s FY26 revenues were derived from customers who had been associated with the firm for more than seven years.

There is a need for careful interpretation when it comes to the 57% market share stated in the title. What this refers to is Symbiotec’s market share of its top five products, instead of a 57% market share in the overall global steroid API industry. The top five products consist of progesterones, hydrocortisones, testosterones, betamethasones and methylprednisolones. Symbiotec considers itself a global leader in hydrocortisone, testosterone and methylprednisolone.

The underlying API business continues to deliver healthy profit margins. During Q1 FY27, API sales grew 6% to Rs 215.3 crore, with API EBITDA climbing 9% to Rs 65.8 crore. Gross margin on APIs stayed north of 60%, with EBITDA margins hovering around 30-31%.

Why Is It Betting on Insulin? 

Insulin marks a significant paradigm shift since the product line does not fall under the category of steroids but is instead a biological molecule. What ties it back to Symbiotec’s overall strategy is not its chemical classification but its manufacturing process, which includes fermentation and biomanufacturing, technologies that can be employed regardless of product type.

The company has inked a five-year take-or-pay contract for the manufacture of the insulin active pharmaceutical ingredient. The firm is making plans to develop the necessary capacity and anticipates filing for regulatory approval in Q4 FY27.

The take-or-pay contract offers the company a definitive route into the realm of biopharmaceutical manufacturing, but commercial success still hinges on whether the company can build out sufficient capacity, obtain necessary regulatory approvals and engage customers effectively. For these reasons, it would be prudent to characterise insulin as an emerging business at present.

Why Alternative Proteins?

Alternative proteins represent yet another application that leverages the same platform capability in terms of fermentation infrastructure. Alternative-protein companies leveraging biotech innovation need significant fermentation, process development, and manufacturing capabilities for their journey from lab innovation into actual commercialisation.

Symbiotec has secured itself a 10-year take-or-pay agreement with a US-based alternative protein company. It also has a 10-year term sheet in place with a European alternative protein player, progressing towards a formal agreement.

There are multiple possibilities beyond those contractual agreements. The management noted several opportunities where more than six potential clients were at advanced stages, and some projects could involve requirements of approximately one million litres of fermentation volumes each. If those pans out, then the company estimates it would need much higher capacities in the next couple of years.

Alternative proteins become strategically distinct from insulin, which is a biopharmaceutical application. On the other hand, alternative proteins fall under industrial biotechnology applications. Still, both applications leverage similar underlying technologies of fermentation and biomanufacturing.

Can the New Businesses Scale?

However, it must be noted that there is also considerable near-term financial risk involved in this opportunity. In Q1 FY27, the consolidated revenue was up 7% to Rs 218.2 crore, although EBITDA dropped to Rs 45.2 crore from Rs 58 crore and PAT came down to Rs 14.1 crore from Rs 29.9 crore. These pressures, at least partially, seem to stem from the company’s newer lines of business. The expenses related to them were estimated at Rs 23 crore, while depreciation charges amounted to Rs 12 crore.

However, management guidance for the year indicates that we may see better numbers in subsequent quarters. Revenue is expected to grow by 20%, with a possible deviation of ±5% due to global risks. Management guidance for FY27 is also 25% higher in terms of EBITDA.

In addition, the company anticipates positive momentum during the second half. Milestone payments along with biotech CDMO revenue are expected to support the business.

Thus, the question would be execution. While the firm has made considerable investments, the newer lines of business still remain smaller compared to the APIs division. It remains to be seen how long it takes to get to full capacity, convert customers, secure regulatory approval and commence commercial production.

The Bigger Growth Bet

Symbiotec’s strategy is ultimately about using its existing strengths to create a new manufacturing platform. The company has a strong steroid API franchise, long-standing global customer relationships and experience in regulated pharmaceutical manufacturing. It is now combining these capabilities with its fermentation expertise to build a biotech-driven CDMO and biomanufacturing business.

The 57% average market share across its top five steroid APIs provides the established base, while insulin and alternative proteins represent new applications for the company’s fermentation capabilities. The signed take-or-pay agreements provide evidence of customer engagement, but the scale of the opportunity will depend on how successfully Symbiotec converts these commitments and its broader pipeline into commercial production.

For investors, the important change is therefore not that Symbiotec is moving away from steroids. It is that a company built around steroid APIs is attempting to develop a second business around biotech, fermentation and CDMO services. If the new capacity reaches the expected utilisation levels and customer programmes scale up, the business mix could gradually become broader. For now, however, the transformation remains in its early stages, making execution of the new investments as important as the strength of its existing steroid franchise.